5-fluoroisoquinoline-1-carbonitrile | 1369292-33-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 5-fluoroisoquinoline-1-carbonitrile
• CAS: 1369292-33-0
• 化学式: C₁₀H₅FN₂
• 分子量: 172.162
• InChiKey: ICTFRQQJSRRRSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-fluoroisoquinoline-1-carbonitrile 在 sodium hydroxide 、 盐酸 作用下， 以 水 为溶剂， 反应 16.0h， 以100%的产率得到5-fluoroisoquinoline-1-carboxylic acid
  参考文献：
  名称：

  HCV NS5A Replication Complex Inhibitors. Part 4.1 Optimization for Genotype 1a Replicon Inhibitory Activity

  摘要：

  A series of symmetrical E-stilbene prolinamides that originated from the library-synthesized lead 3 was studied with respect to HCV genotype 1a (G-1a) and genotype 1b (G-1b) replicon inhibition and selectivity against BVDV and cytotoxicity. SAR emerging from an examination of the prolinamide cap region revealed 11 to be a selective HCV NS5A inhibitor exhibiting submicromolar potency against both G-1a and G-1b replicons. Additional structural refinements resulted in the identification of 30 as a potent, dual G-1a/1b HCV NS5A inhibitor.

  DOI：

  10.1021/jm301796k
• 作为产物：
  描述：

  potassium cyanide 、 1-氯-5-氟异喹啉 在 四甲基乙二胺 、 1,5-双(二苯基膦)戊烷 、 palladium diacetate 作用下， 以 甲苯 为溶剂， 以28%的产率得到5-fluoroisoquinoline-1-carbonitrile
  参考文献：
  名称：

  HCV NS5A Replication Complex Inhibitors. Part 4.1 Optimization for Genotype 1a Replicon Inhibitory Activity

  摘要：

  A series of symmetrical E-stilbene prolinamides that originated from the library-synthesized lead 3 was studied with respect to HCV genotype 1a (G-1a) and genotype 1b (G-1b) replicon inhibition and selectivity against BVDV and cytotoxicity. SAR emerging from an examination of the prolinamide cap region revealed 11 to be a selective HCV NS5A inhibitor exhibiting submicromolar potency against both G-1a and G-1b replicons. Additional structural refinements resulted in the identification of 30 as a potent, dual G-1a/1b HCV NS5A inhibitor.

  DOI：

  10.1021/jm301796k

文献信息

• QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS
  申请人：Laboratorios del Dr. Esteve, S.A.

  公开号：EP3339304A1

  公开（公告）日：2018-06-27

  The present invention relates to new compounds of formula (I): showing great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels or dual activity towards subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels, and the noradrenaline transporter (NET).

  本发明涉及公式（I）的新化合物：对电压门控钙通道（VGCC）的亚单位α2δ具有很高的亲和力和活性，特别是对电压门控钙通道的α2δ-1亚单位或对电压门控钙通道的亚单位α2δ（VGCC）具有双重活性，特别是对电压门控钙通道的α2δ-1亚单位，以及去甲肾上腺素转运体（NET）。
• Quinoline and isoquinoline derivatives for treating pain and pain related conditions
  申请人：ESTEVE PHARMACEUTICALS, S.A.

  公开号：US10941138B2

  公开（公告）日：2021-03-09

  The present invention relates to new compounds of formula (I): showing great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels or dual activity towards subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels, and the noradrenaline transporter (NET).

  本发明涉及新的式（I）化合物： 对电压门控钙通道（VGCC）的α2δ亚基，特别是电压门控钙通道的α2δ-1亚基表现出极大的亲和力和活性，或对电压门控钙通道（VGCC）的α2δ亚基，特别是电压门控钙通道的α2δ-1亚基和去甲肾上腺素转运体（NET）表现出双重活性。
• NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS
  申请人：ESTEVE PHARMACEUTICALS, S.A.

  公开号：EP3558965A1

  公开（公告）日：2019-10-30
• [EN] NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS<br/>[FR] NOUVEAUX DÉRIVÉS DE QUINOLÉINE ET D'ISOQUINOLÉINE POUR TRAITER LA DOULEUR ET LES ÉTATS PATHOLOGIQUES ASSOCIÉS À LA DOULEUR
  申请人：ESTEVE LABOR DR

  公开号：WO2018115064A1

  公开（公告）日：2018-06-28

  The present invention relates to new compounds of formula (I): showing great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1subunit of voltage-gated calcium channels or dual activity towards subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1subunit of voltage-gated calcium channels, and the noradrenaline transporter (NET).